Sosei heptares' partner neurocrine biosciences confirms its plans to evaluate two new muscarinic agonist candidates in phase 1 clinical studies

Tokyo, japan and cambridge, uk, 6 december 2023 – sosei group corporation (“the company”; tse: 4565), notes its partner neurocrine biosciences inc. (“neurocrine”; nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in phase 1 first-in-human clinical studies. the studies are designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nbi-1117569 and nbi-1117567 in healthy adult participants. nbi-1117569, a muscarinic m4-preferring agonist, and nbi-1117567, a muscarinic m1-preferring agonist are both investigational, oral compounds that may have the potential to treat neurological and neuropsychiatric conditions and were developed utilizing sosei heptares' structure-based drug design platform. neurocrine confirmed a phase 1 clinical study of nbi-1117569 has started and a phase 1 study of nbi-1117567 will be initiated in 2024.
NBIX Ratings Summary
NBIX Quant Ranking